

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype ()
predictive factor in breast cancer

Nature Genetics

40, 844-853

DOI: 10.1038/ng.155

Citation Report

#	ARTICLE	IF	CITATIONS
1	γ H2AX and cancer. Nature Reviews Cancer, 2008, 8, 957-967.	12.8	1,423
2	Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Molecular Oncology, 2008, 2, 296-316.	2.1	147
3	The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Research, 2008, 10, R108.	2.2	49
4	A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis. Breast Cancer Research, 2008, 10, 109.	2.2	13
5	Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. Breast Care, 2008, 3, 401-406.	0.8	2
6	Basic science: (July 2008). Breast Cancer Online: BCO, 2008, 11, .	0.1	0
7	Coordinate Control of Expression of Nrf2-Modulated Genes in the Human Small Airway Epithelium Is Highly Responsive to Cigarette Smoking. Molecular Medicine, 2009, 15, 203-219.	1.9	80
8	Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Human Molecular Genetics, 2009, 18, 2502-2517.	1.4	31
9	Identification of Novel Susceptibility Genes for Breast Cancer – Genome-Wide Association Studies or Evaluation of Candidate Genes?. Breast Care, 2009, 4, 93-99.	0.8	8
10	The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype. Clinical Cancer Research, 2009, 15, 3214-3222.	3.2	122
11	Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochemical Pharmacology, 2009, 78, 344-354.	2.0	38
12	The effect of genetic variability on drug response in conventional breast cancer treatment. European Journal of Pharmacology, 2009, 625, 122-130.	1.7	32
13	Case-only genome-wide interaction study of disease risk, prognosis and treatment. Genetic Epidemiology, 2010, 34, 7-15.	0.6	22
14	Fifty Years of Nucleic Acid Electrochemistry. Electroanalysis, 2009, 21, 239-251.	1.5	86
15	Breast cancer susceptibility: current knowledge and implications for genetic counselling. European Journal of Human Genetics, 2009, 17, 722-731.	1.4	171
16	Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Molecular Psychiatry, 2009, 14, 563-589.	4.1	211
17	p53 polymorphisms: cancer implications. Nature Reviews Cancer, 2009, 9, 95-107.	12.8	564
19	Commentary: Antioxidants for Cancer: New Tricks for an Old Dog?. Oncologist, 2009, 14, 213-215.	1.9	11

#	ARTICLE	IF	CITATIONS
20	Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 381-387.	6.6	34
21	Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R89.	2.2	35
22	NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 505-512.	0.7	6
23	Association between mitochondrial DNA 4,977 bp deletion and NAD(P)H:quinone oxidoreductase 1 C609T polymorphism in human breast tissues. <i>Oncology Reports</i> , 2009, 21, 1169-74.	1.2	16
24	Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 129.	0.4	8
25	Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 467-474.	1.1	52
26	CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 87-93.	1.1	22
27	Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 585-591.	1.1	73
28	Ubiquitin-independent p53 proteasomal degradation. <i>Cell Death and Differentiation</i> , 2010, 17, 103-108.	5.0	120
29	NAD(P)H Quinone Oxidoreductase Protects TAp63 ^{Δ3} from Proteasomal Degradation and Regulates TAp63 ^{Δ3} -Dependent Growth Arrest. <i>PLoS ONE</i> , 2010, 5, e11401.	1.1	21
30	Zeptomole Electrochemical Detection of Metallothioneins. <i>PLoS ONE</i> , 2010, 5, e11441.	1.1	56
31	Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. <i>Neoplasma</i> , 2010, 57, 415-421.	0.7	25
32	A Genome-Wide Association Study of Prognosis in Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1140-1143.	1.1	57
33	The Influence of Common Polymorphisms on Breast Cancer. <i>Cancer Treatment and Research</i> , 2010, 155, 15-32.	0.2	12
34	A Functional Polymorphism in the NAD(P)H Oxidase Subunit <i>CYBA</i> Is Related to Gene Expression, Enzyme Activity, and Outcome in Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2010, 70, 2328-2338.	0.4	21
35	Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility. <i>PLoS Genetics</i> , 2010, 6, e1001012.	1.5	41
36	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. <i>PLoS Medicine</i> , 2010, 7, e1000279.	3.9	764
37	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor- α Negative Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2010, 102, 650-662.	3.0	48

#	ARTICLE	IF	CITATIONS
38	Paradoxical roles for antioxidants in tumor prevention and eradication. <i>Cancer Biology and Therapy</i> , 2010, 9, 362-370.	1.5	16
39	A genome-wide association scan on estrogen receptor-negative breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R93.	2.2	35
40	Microarray-Based Detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and ABO Allele Frequencies in Native Russians. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 329-342.	0.3	36
41	NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. <i>Archives of Biochemistry and Biophysics</i> , 2010, 501, 116-123.	1.4	579
42	DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. <i>Free Radical Research</i> , 2011, 45, 276-292.	1.5	12
44	Pharmacogenetics of genes across the doxorubicin pathway. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1201-1210.	1.5	29
45	Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R10.	2.2	15
46	Breast tumors from CHEK2 1100delC- mutation carriers: genomic landscape and clinical implications. <i>Breast Cancer Research</i> , 2011, 13, R90.	2.2	55
47	Variants on the promoter region of PTEN affect breast cancer progression and patient survival. <i>Breast Cancer Research</i> , 2011, 13, R130.	2.2	43
48	Global Gene Expression Profiling of Endothelium Exposed to Heme Reveals an Organ-Specific Induction of Cytoprotective Enzymes in Sickle Cell Disease. <i>PLoS ONE</i> , 2011, 6, e18399.	1.1	24
49	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 808-819.	0.7	30
50	C609T Polymorphism of NAD(P)H Quinone Oxidoreductase 1 As a Predictive Biomarker for Response to Amrubicin. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1826-1832.	0.5	7
51	Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 467-472.	1.1	22
52	L-methionine-induced alterations in molecular signatures in MCF-7 and LNCaP cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 441-453.	1.2	6
53	The cytoprotective role of the Keap1-Nrf2 pathway. <i>Archives of Toxicology</i> , 2011, 85, 241-272.	1.9	830
54	Familial Mortality and Familial Incidence in Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 712-718.	0.8	21
55	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of Î²-Lapachone for Pancreatic Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 275-285.	3.2	96
56	Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. <i>Carcinogenesis</i> , 2011, 32, 1107-1121.	1.3	102

#	ARTICLE	IF	CITATIONS
57	Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2012, 13, 16500-16513.	1.8	5
58	Liver enzymes in White Leghorns selected for the sheep red blood cell immune response. <i>Poultry Science</i> , 2012, 91, 322-326.	1.5	14
59	Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs. <i>Current Cancer Drug Targets</i> , 2012, 12, 402-438.	0.8	57
60	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. <i>British Journal of Cancer</i> , 2012, 107, 800-807.	2.9	163
61	Novel Genetic Markers of Breast Cancer Survival Identified by a Genome-Wide Association Study. <i>Cancer Research</i> , 2012, 72, 1182-1189.	0.4	62
62	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	1.4	80
63	Combined experimental and computational analysis of DNA damage signaling reveals contextâ€dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. <i>Molecular Systems Biology</i> , 2012, 8, 568.	3.2	72
64	Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy. <i>Cancer Investigation</i> , 2012, 30, 663-678.	0.6	18
65	Electrochemistry of Nucleic Acids. <i>Chemical Reviews</i> , 2012, 112, 3427-3481.	23.0	583
66	Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. <i>Molecular Genetics and Genomics</i> , 2012, 287, 755-764.	1.0	8
67	An NQO1-Initiated and p53-Independent Apoptotic Pathway Determines the Anti-Tumor Effect of Tanshinone IIA against Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e42138.	1.1	70
68	Genetic Variants in Oxidative Stressâ€Related Genes Predict Chemoresistance in Primary Breast Cancer: A Prospective Observational Study and Validation. <i>Cancer Research</i> , 2012, 72, 408-419.	0.4	24
69	NQO1 expression correlates inversely with NFÎB activation in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 955-968.	1.1	23
70	NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. <i>Biochemical Pharmacology</i> , 2012, 83, 1033-1040.	2.0	233
71	Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. <i>International Journal of Cancer</i> , 2012, 130, 338-348.	2.3	50
72	Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. <i>International Journal of Cancer</i> , 2012, 130, 2103-2110.	2.3	15
73	Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients â€ Potential differential effects by radiotherapy?. <i>Breast</i> , 2013, 22, 817-823.	0.9	31
74	Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). <i>Annals of Oncology</i> , 2013, 24, 1513-1525.	0.6	57

#	ARTICLE	IF	CITATIONS
75	Detection of single nucleotide polymorphisms by PCR conformation-difference gel electrophoresis. <i>Biotechnology Letters</i> , 2013, 35, 515-522.	1.1	5
76	Identification of genetic markers with synergistic survival effect in cancer. <i>BMC Systems Biology</i> , 2013, 7, S2.	3.0	1
77	Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides. <i>Free Radical Research</i> , 2013, 47, 1016-1026.	1.5	7
78	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2013, 132, 2044-2055.	2.3	11
79	C609T polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S10839.	0.6	10
80	<i>HOXB13</i> C84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 452-460.	1.1	75
81	Identification of Inherited Genetic Variations Influencing Prognosis in Early-Onset Breast Cancer. <i>Cancer Research</i> , 2013, 73, 1883-1891.	0.4	42
82	NAD(P)H: Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Polymorphisms in Papillary Thyroid Microcarcinoma: Correlation with Phenotype. <i>Yonsei Medical Journal</i> , 2013, 54, 1158.	0.9	9
83	A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis. <i>PLoS ONE</i> , 2014, 9, e101488.	1.1	42
84	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e116027.	1.1	22
86	The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1-10.	2.8	44
87	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 667-674.	1.1	32
88	Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase 1. <i>FEBS Journal</i> , 2014, 281, 4691-4704.	2.2	60
89	Metabolism (Non-CYP Enzymes). <i>Cancer Drug Discovery and Development</i> , 2014, , 229-254.	0.2	1
90	Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 437-441.	1.1	1
91	Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. <i>Pharmacogenomics</i> , 2014, 15, 329-337.	0.6	49
92	The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 293-299.	3.4	45
93	Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 557-570.	1.1	23

#	ARTICLE	IF	CITATIONS
94	NQO1 Suppresses NF- κ B-p300 Interaction to Regulate Inflammatory Mediators Associated with Prostate Tumorigenesis. <i>Cancer Research</i> , 2014, 74, 5644-5655.	0.4	41
96	Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers. <i>Scientific Reports</i> , 2015, 5, 14499.	1.6	29
97	Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. <i>Scientific Reports</i> , 2014, 4, 6566.	1.6	61
98	Activation of NQO1 in NQO1*2 polymorphic human leukemic HL-60 cells by diet-derived sulforaphane. <i>Experimental Hematology and Oncology</i> , 2015, 5, 27.	2.0	8
99	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	2.2	26
100	Detection of novel germline mutations for breast cancer in non-BRCA1/2 families. <i>FEBS Journal</i> , 2015, 282, 3424-3437.	2.2	50
101	WDR5 Expression Is Prognostic of Breast Cancer Outcome. <i>PLoS ONE</i> , 2015, 10, e0124964.	1.1	72
102	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	0.8	20
103	Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients. <i>Biochemical Genetics</i> , 2015, 53, 211-222.	0.8	5
104	ROS and energy metabolism in cancer cells: alliance for fast growth. <i>Archives of Pharmacal Research</i> , 2015, 38, 338-345.	2.7	86
105	Cooperation of DLC1 and CDK6 Affects Breast Cancer Clinical Outcome. <i>G3: Genes, Genomes, Genetics</i> , 2015, 5, 81-91.	0.8	17
106	Over-expression of EPS15 is a favorable prognostic factor in breast cancer. <i>Molecular BioSystems</i> , 2015, 11, 2978-2985.	2.9	6
107	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	56
108	RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. <i>SpringerPlus</i> , 2015, 4, 92.	1.2	21
109	NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. <i>BMC Cancer</i> , 2015, 15, 207.	1.1	76
110	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1139-1149.	1.6	23
111	Cabbage Juices and Indoles Modulate the Expression Profile of AhR, ER α , and Nrf2 in Human Breast Cell Lines. <i>Nutrition and Cancer</i> , 2015, 67, 1344-1356.	0.9	16
112	Antioxidant response genes sequence variants and BPD susceptibility in VLBW infants. <i>Pediatric Research</i> , 2015, 77, 477-483.	1.1	52

#	ARTICLE	IF	CITATIONS
113	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. <i>Human Molecular Genetics</i> , 2015, 24, 7406-7420.	1.4	17
114	<sc>NAD</sc>(P)H dehydrogenase, quinone 1 (<sc>NQO</sc>1), protects melanin-producing cells from cytotoxicity of rhododendrol. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 309-316.	1.5	16
115	Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer. <i>Medical Oncology</i> , 2016, 33, 112.	1.2	4
116	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 463-469.	1.1	24
117	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2016, 139, 2760-2770.	2.3	13
118	Exploring the intrinsic differences among breast tumor subtypes defined using immunohistochemistry markers based on the decision tree. <i>Scientific Reports</i> , 2016, 6, 35773.	1.6	17
119	Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. <i>Molecular Cancer Research</i> , 2016, 14, 14-25.	1.5	50
120	Survival in familial and non-familial breast cancer by age and stage at diagnosis. <i>European Journal of Cancer</i> , 2016, 52, 10-18.	1.3	14
121	Pharmacogenetic Predictors of Response. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 191-215.	0.8	4
123	Whole genome and normalized mRNA sequencing reveal genetic status of TK6, WTK1, and NH32 human B-lymphoblastoid cell lines. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2016, 795, 60-69.	0.9	10
124	DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. <i>Molecular Oncology</i> , 2016, 10, 879-894.	2.1	41
125	Screening of HELQ in breast and ovarian cancer families. <i>Familial Cancer</i> , 2016, 15, 19-23.	0.9	7
126	Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients. <i>World Journal of Surgery</i> , 2016, 40, 1600-1610.	0.8	7
127	Replication stress, <sc>DNA</sc> damage signalling, and cytomegalovirus infection in human medulloblastomas. <i>Molecular Oncology</i> , 2017, 11, 945-964.	2.1	11
128	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. <i>Scientific Reports</i> , 2017, 7, 681.	1.6	20
129	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 217-226.	1.1	26
130	Expression of <sc>NAD</sc>(P)H quinone dehydrogenase 1 (<sc>NQO</sc>1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 557-565.	1.2	14
131	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017, 8, 1632.	5.8	18

#	ARTICLE	IF	CITATIONS
132	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678.	0.8	21
133	Azoreductases in drug metabolism. <i>British Journal of Pharmacology</i> , 2017, 174, 2161-2173.	2.7	64
134	Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of Î²-lapachone in melanoma cell lines. <i>Oncology Letters</i> , 2017, 15, 2393-2400.	0.8	10
135	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. <i>BMC Cancer</i> , 2017, 17, 620.	1.1	29
136	Rosiglitazone pretreatment influences thrombin-induced anti-oxidative action via activating NQO1 and Î²-GCS in rat microglial cells. <i>Neurological Research</i> , 2018, 40, 139-145.	0.6	5
137	Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy. <i>Familial Cancer</i> , 2018, 17, 321-331.	0.9	4
138	Sex Differences in Cancer: Epidemiology, Genetics and Therapy. <i>Biomolecules and Therapeutics</i> , 2018, 26, 335-342.	1.1	178
139	Ethnic Differences in Susceptibility to the Effects of Platinum- Based Chemotherapy. , 0, , .		2
140	A two-photon ratiometric probe for detection of hNQO1 enzyme activity in human colon tissue. <i>Sensors and Actuators B: Chemical</i> , 2018, 272, 203-210.	4.0	24
141	Colorectal cancer: pharmacogenetics support for the correct drug prescription. <i>Pharmacogenomics</i> , 2019, 20, 741-763.	0.6	5
142	Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 510.	1.5	30
143	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2692-2700.	2.3	19
144	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
145	<i><sc>NQO</sc>1*2</i> polymorphism predicts overall survival in <sc>MDS</sc> patients. <i>British Journal of Haematology</i> , 2019, 184, 305-308.	1.2	2
146	A small molecule chaperone rescues the stability and activity of a cancer-associated variant of NAD(P)H:quinone oxidoreductase 1 <i>in vitro</i>. <i>FEBS Letters</i> , 2020, 594, 424-438.	1.3	7
147	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
148	Cell Cycle and Factors Involved in Inhibition or Progression of Breast Cancer. , 2020, , .		1
149	Activating PPARÎ³ Increases NQO1 and Î²-GCS Expression via Nrf2 in Thrombin-activated Microglia. <i>Current Medical Science</i> , 2020, 40, 55-62.	0.7	3

#	ARTICLE	IF	CITATIONS
150	The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico. <i>Frontiers in Pharmacology</i> , 2020, 11, 324.	1.6	8
151	Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 823-837.	1.1	5
152	Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 133-139.	0.7	2
153	NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis. <i>Anticancer Research</i> , 2021, 41, 1563-1570.	0.5	5
154	Single nucleotide polymorphisms as the efficient prognostic markers in breast cancer. <i>Current Cancer Drug Targets</i> , 2021, 21, .	0.8	0
155	Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. <i>World Journal of Gastroenterology</i> , 2021, 27, 3085-3096.	1.4	3
156	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 14763.	1.6	3
157	Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. <i>Mutation Research - Reviews in Mutation Research</i> , 2021, 788, 108391.	2.4	4
158	High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. <i>PLoS Genetics</i> , 2021, 17, e1009732.	1.5	6
159	Flavins and Flavoproteins: Applications in Medicine. <i>Methods in Molecular Biology</i> , 2014, 1146, 113-157.	0.4	10
160	ARTEMIS: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1144-TPS1144.	0.8	2
161	Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma. <i>PLoS ONE</i> , 2012, 7, e40521.	1.1	35
162	Long Term Effect of Curcumin in Restoration of Tumour Suppressor p53 and Phase-II Antioxidant Enzymes via Activation of Nrf2 Signalling and Modulation of Inflammation in Prevention of Cancer. <i>PLoS ONE</i> , 2015, 10, e0124000.	1.1	101
163	Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. <i>PLoS ONE</i> , 2015, 10, e0134463.	1.1	19
164	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	0.8	14
165	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	0.8	15
166	The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 1215-1219.	0.5	4
167	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0

#	ARTICLE	IF	CITATIONS
168	Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2011, 4, 363-70.	0.5	16
169	Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 618.	1.1	1
171	The Prevalence of Pharmacogenomics Variants and Their Clinical Relevance Among the Pakistani Population. <i>Evolutionary Bioinformatics</i> , 2022, 18, 117693432210958.	0.6	1
172	A Presurgicalâ€Window Intervention Trial of Isothiocyanateâ€Rich Broccoli Sprout Extract in Patients with Breast Cancer. <i>Molecular Nutrition and Food Research</i> , 2022, , 2101094.	1.5	5
173	The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability. <i>Oncogene</i> , 2022, 41, 5107-5120.	2.6	14
175	Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients. <i>Cancers</i> , 2022, 14, 6158.	1.7	2
176	Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer. <i>Toxicology and Applied Pharmacology</i> , 2023, 460, 116375.	1.3	3